Free Trial
NASDAQ:BLRX

BioLineRx Q2 2025 Earnings Report

BioLineRx logo
$3.87 -0.11 (-2.76%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$3.92 +0.05 (+1.42%)
As of 08/1/2025 04:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioLineRx EPS Results

Actual EPS
N/A
Consensus EPS
-$0.35
Beat/Miss
N/A
One Year Ago EPS
N/A

BioLineRx Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

BioLineRx Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Thursday, August 14, 2025
Conference Call Time
8:30AM ET

Conference Call Resources

BioLineRx Earnings Headlines

$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.
15 Best Growth Stocks to Invest in for the Next 5 Years
BioLineRx upgraded to Buy from Hold at JonesResearch
See More BioLineRx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BioLineRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioLineRx and other key companies, straight to your email.

About BioLineRx

BioLineRx (NASDAQ:BLRX), a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

View BioLineRx Profile

More Earnings Resources from MarketBeat